Log in

NASDAQ:OVIDOvid Therapeutics Stock Price, Forecast & News

$5.29
-0.15 (-2.76 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.27
Now: $5.29
$5.80
50-Day Range
$3.18
MA: $4.24
$6.69
52-Week Range
$1.53
Now: $5.29
$7.21
Volume1.37 million shs
Average Volume1.34 million shs
Market Capitalization$289.63 million
P/E RatioN/A
Dividend YieldN/A
Beta2.2
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Read More
Ovid Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OVID
CUSIPN/A
Phone646-661-7661

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.46 per share

Profitability

Net Income$-60,460,000.00

Miscellaneous

Employees59
Market Cap$289.63 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

How has Ovid Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 97.4% and is now trading at $5.29. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ovid Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ovid Therapeutics.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Ovid Therapeutics.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc (NASDAQ:OVID) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.04. View Ovid Therapeutics' earnings history.

What price target have analysts set for OVID?

6 brokers have issued twelve-month price objectives for Ovid Therapeutics' stock. Their forecasts range from $10.00 to $20.00. On average, they anticipate Ovid Therapeutics' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 164.7% from the stock's current price. View analysts' price targets for Ovid Therapeutics.

Has Ovid Therapeutics been receiving favorable news coverage?

Press coverage about OVID stock has trended positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ovid Therapeutics earned a news sentiment score of 2.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutOvid Therapeutics.

Are investors shorting Ovid Therapeutics?

Ovid Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,650,000 shares, an increase of 20.4% from the April 30th total of 1,370,000 shares. Based on an average trading volume of 602,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 5.7% of the company's shares are sold short. View Ovid Therapeutics' Current Options Chain.

Who are some of Ovid Therapeutics' key competitors?

What other stocks do shareholders of Ovid Therapeutics own?

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the following people:
  • Dr. Jeremy Max Levin, Chairman & CEO (Age 67, Pay $821.32k)
  • Dr. Amit Rakhit, Pres & Chief Medical Officer (Age 50, Pay $694.05k)
  • Mr. Timothy G. Daly, Exec. VP of Fin., Treasurer & Corp. Controller (Age 49, Pay $439.45k)
  • Dr. Matthew J. During, Founder & Chairman of Scientific Advisory Board (Age 63)
  • Ms. Lora Pike, Sr. Director of Investor Relations & PR

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include AXA (1.49%), BlackRock Inc. (0.89%), Wells Fargo & Company MN (0.89%), Ikarian Capital LLC (0.69%), Geode Capital Management LLC (0.54%) and UBS Group AG (0.38%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View institutional ownership trends for Ovid Therapeutics.

Which major investors are selling Ovid Therapeutics stock?

OVID stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, JPMorgan Chase & Co., Acadian Asset Management LLC, Blair William & Co. IL, EAM Investors LLC, AXA, and Squarepoint Ops LLC. View insider buying and selling activity for Ovid Therapeutics.

Which major investors are buying Ovid Therapeutics stock?

OVID stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Connor Clark & Lunn Investment Management Ltd., Assenagon Asset Management S.A., Jane Street Group LLC, BlackRock Inc., Wedbush Securities Inc., Ikarian Capital LLC, and Shufro Rose & Co. LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein, and Pharmaceutical Co Ltd Takeda. View insider buying and selling activity for Ovid Therapeutics.

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $5.29.

How big of a company is Ovid Therapeutics?

Ovid Therapeutics has a market capitalization of $289.63 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Ovid Therapeutics employs 59 workers across the globe.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is www.ovidrx.com.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.